These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24935574)

  • 1. Survival and prognostic factors for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience.
    Abdelaziz AO; Elbaz TM; Shousha HI; Ibrahim MM; Rahman El-Shazli MA; Abdelmaksoud AH; Aziz OA; Zaki HA; Elattar IA; Nabeel MM
    Asian Pac J Cancer Prev; 2014; 15(9):3915-20. PubMed ID: 24935574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new prognostic score can predict survival after hepatocellular carcinoma treatment in a cohort of 1302 Egyptian hepatocellular carcinoma patients.
    Abdelaziz AO; Shousha HI; Abdelmaksoud AH; Saad Y; Elbaz TM; Soliman ZA; Salah A; Lithy R; Ahmed M; Nabil MM
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):514-519. PubMed ID: 29465472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
    Waziry R; Gomaa A; Waked I; Dore GJ
    Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.
    Mondazzi L; Bottelli R; Brambilla G; Rampoldi A; Rezakovic I; Zavaglia C; Alberti A; Idèo G
    Hepatology; 1994 May; 19(5):1115-23. PubMed ID: 7513677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
    Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
    J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Prajapati HJ; Kim HS
    PLoS One; 2017; 12(2):e0170750. PubMed ID: 28170405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoembolization of recurrent hepatoma after curative resection: prognostic factors.
    Zu QQ; Liu S; Zhou CG; Yang ZQ; Xia JG; Zhao LB; Shi HB
    AJR Am J Roentgenol; 2015 Jun; 204(6):1322-8. PubMed ID: 26001244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: Experience from a Cohort of 421 Patients at an Italian Center.
    Aliberti C; Carandina R; Lonardi S; Dadduzio V; Vitale A; Gringeri E; Zanus G; Cillo U
    J Vasc Interv Radiol; 2017 Nov; 28(11):1495-1502. PubMed ID: 28927662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival.
    Roberts SK; Gazzola A; Lubel J; Gow P; Bell S; Nicoll A; Dev A; Fink MA; Sood S; Knight V; Hong T; Paul E; Mishra G; Majeed A; Kemp W;
    Scand J Gastroenterol; 2018; 53(10-11):1368-1375. PubMed ID: 30394145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies.
    Chen BB; Shih IL; Wu CH; Hsu C; Chen CH; Shih TT; Liu KL; Liang PC
    J Vasc Interv Radiol; 2014 Mar; 25(3):371-8. PubMed ID: 24468045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
    Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
    Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization.
    Kim NH; Lee T; Cho YK; Kim BI; Kim HJ
    J Gastroenterol Hepatol; 2018 Jul; 33(7):1397-1406. PubMed ID: 29314222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial Chemoembolization versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma after Resection within Barcelona Clinic Liver Cancer Stage 0/A: A Retrospective Comparative Study.
    Chen R; Gan Y; Ge N; Chen Y; Wang Y; Zhang B; Wang Y; Ye S; Ren Z
    J Vasc Interv Radiol; 2016 Dec; 27(12):1829-1836. PubMed ID: 27553917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.
    Ni JY; Sun HL; Chen YT; Luo JH; Chen D; Jiang XY; Xu LF
    World J Gastroenterol; 2014 Dec; 20(46):17483-90. PubMed ID: 25516662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HAP score as prognostic factor of hepatocellular carcinoma treated with transarterial chemoembolization in a Latin American center.
    Liza Baca E; Díaz Ferrer J
    Rev Gastroenterol Peru; 2018; 38(2):164-168. PubMed ID: 30118463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma in Danish patients: a single Copenhagen center experience.
    Stefansdottir J; Christensen E; Schiødt FV
    Scand J Gastroenterol; 2017; 52(6-7):768-772. PubMed ID: 28355956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.
    Kim JH; Sinn DH; Lee JH; Hyun D; Cho SK; Shin SW; Chang Y; Kim YJ; Yoon JH; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS
    Dig Dis Sci; 2018 Apr; 63(4):1062-1071. PubMed ID: 29442276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.